Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITATI: bNAbs and ATI in HIV+ allo-HSCT recipients
NCT04720742Phase 2Withdrawn
- Sponsor
- IrsiCaixa
- Start
- Feb 2021
- Primary completion
- Mar 2022
- Modality
- Anti-infectious Disease mAbs
- Countries
- 3
01
Overview
A Phase 2 trial of Teropavimab, zinlirvimab in human immunodeficiency virus infection (HIV), sponsored by IrsiCaixa. Planned start Feb 2021; status: withdrawn.
02
Drugs
Teropavimabzinlirvimab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04720742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04720742.